Drugs Acting on the Gut: Prokinetics, Antispasmodics, Laxatives

Disorders of gastrointestinal motility result from abnormal contractions of the smooth muscles of the gastrointestinal tract. This may result in diarrhea and bloating or constipation with or without accompanying abdominal pain. Drugs that act on the gastrointestinal tract may be categorized into three groups: (1) agents that enhance smooth muscle contractions, referred to as prokinetic agents; (2) agents that inhibit contractions, which may be agents that retard normal peristalsis referred to as antimotility agents (opiates and opiate receptor agonists), or agents that reduce abnormally elevated gastrointestinal smooth muscle tone, referred to as antispasmodics (anticholinergics, direct smooth muscle relaxers, and calcium channel blockers); and (3) agents that act to promote evacuation of stool, referred to as laxatives. This chapter will discuss prokinetics, antimotility agents, and antispasmodics, as well as laxatives commonly used in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic €32.70 /Month

Buy Now

Price includes VAT (France)

eBook EUR 106.99 Price includes VAT (France)

Softcover Book EUR 137.14 Price includes VAT (France)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Similar content being viewed by others

Drugs Acting on the Gut: Prokinetics, Antispasmodics, Laxatives

Chapter © 2013

Antacids, Gastrointestinal Prokinetics, and Proton Pump Inhibitors

Chapter © 2015

Top 10 Drugs Most Commonly Used for GI Motility Disorders

Chapter © 2018

References

  1. Hofmeyr GJ, Van Iddekinge B, Blott JA. Domperidone: secretion in breast milk and effect on puerperal prolactin levels. Br J Obstet Gynaecol. 1985;92(2):141–4. ArticleCASPubMedGoogle Scholar
  2. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ. 1986;135(5):457–61. CASPubMedPubMed CentralGoogle Scholar
  3. Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet. 1981;6(1):61–70. ArticleCASPubMedGoogle Scholar
  4. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036–45. ArticleCASPubMedGoogle Scholar
  5. Van Eygen M, Dhondt F, Heck E, et al. A double-blind comparison of domperidone and metoclopramide suppositories in the treatment of nausea and vomiting in children. Postgrad Med J. 1979;55 Suppl 1:36–9. PubMedGoogle Scholar
  6. Kita F, Hinotsu S, Yorifuji T, et al. Domperidone with ORT in the treatment of pediatric acute gastroenteritis in Japan: a multicenter, randomized controlled trial. Asia Pac J Public Health. 2015;27(2):NP174–83. ArticlePubMedGoogle Scholar
  7. Bines JE, Quinlan JE, Treves S, et al. Efficacy of domperidone in infants and children with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1992;14(4):400–5. ArticleCASPubMedGoogle Scholar
  8. Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs. 2009;11(3):185–202. ArticlePubMedGoogle Scholar
  9. Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol. 2005;59(6):725–9. ArticleCASPubMedPubMed CentralGoogle Scholar
  10. Cresi F, Marinaccio C, Russo MC, et al. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring. J Perinatol. 2008;28(11):766–70. ArticleCASPubMedGoogle Scholar
  11. Djeddi D, Kongolo G, Lefaix C, et al. Effect of domperidone on QT interval in neonates. J Pediatr. 2008;153(5):663–6. ArticleCASPubMedGoogle Scholar
  12. Gunlemez A, Babaoglu A, Arisoy AE, et al. Effect of domperidone on the QTc interval in premature infants. J Perinatol. 2010;30(1):50–3. ArticleCASPubMedGoogle Scholar
  13. Ngoenmak T, Treepongkaruna S, Buddharaksa Y, et al. Effects of domperidone on QT interval in children with gastroesophageal reflux disease. Pediatr Neonatol. 2015;57(1):60–4. ArticlePubMedGoogle Scholar
  14. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6(7):726–33. ArticlePubMedGoogle Scholar
  15. Maton PN. Profile and assessment of GERD pharmacotherapy. Cleve Clin J Med. 2003;70(5):S51–70. ArticlePubMedGoogle Scholar
  16. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96(3):689–96. ArticleCASPubMedGoogle Scholar
  17. Hamers J. Cytostatic therapy-induced vomiting inhibited by domperidone. A double-blind cross-over study. Biomedicine. 1978;29(7):242–4. CASPubMedGoogle Scholar
  18. Huys J. Cytostatic-associated vomiting effectively inhibited by domperidone (R 33 812). Cancer Chemother Pharmacol. 1978;1(4):215–8. ArticleCASPubMedGoogle Scholar
  19. Zegveld C, Knape H, Smits J, et al. Domperidone in the treatment of postoperative vomiting: a double-blind multicenter study. Anesth Analg. 1978;57(6):700–3. ArticleCASPubMedGoogle Scholar
  20. van Leeuwen L, Helmers JH. The efficacy of domperidone (R 33812) in the treatment of postoperative vomiting. A double-blind study with a placebo. Anaesthesist. 1980;29(9):490–3. PubMedGoogle Scholar
  21. Osborne RJ, Slevin ML, Hunter RW, et al. Cardiotoxicity of intravenous domperidone. Lancet. 1985;2(8451):385. ArticleCASPubMedGoogle Scholar
  22. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J (Clin Res Ed). 1984;289(6458):1579. ArticleCASGoogle Scholar
  23. Ortiz A, Cooper CJ, Alvarez A, et al. Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. Am J Med Sci. 2015;349(5):421–4. ArticlePubMedPubMed CentralGoogle Scholar
  24. Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(9):881–8. ArticlePubMedGoogle Scholar
  25. Arana A, Johannes CB, McQuay LJ, et al. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study. Drug Saf. 2015;38(12):1187–99. ArticleCASPubMedPubMed CentralGoogle Scholar
  26. van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33(11):1003–14. ArticlePubMedGoogle Scholar
  27. Brock-Utne JG, Dimopoulos GE, Downing JW, et al. Effect of metoclopramide given before atropine sulphate on lower oesophageal sphincter tone. S Afr Med J. 1982;61(13):465–7. CASPubMedGoogle Scholar
  28. McCallum RW, Kline MM, Curry N, et al. Comparative effects of metoclopramide and bethanechol on lower esophageal sphincter pressure in reflux patients. Gastroenterology. 1975;68(5 Pt 1):1114–8. CASPubMedGoogle Scholar
  29. Yis U, Ozdemir D, Duman M, et al. Metoclopramide induced dystonia in children: two case reports. Eur J Emerg Med. 2005;12(3):117–9. ArticlePubMedGoogle Scholar
  30. Hyams JS, Leichtner AM, Zamett LO, et al. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1986;5(5):716–20. ArticleCASPubMedGoogle Scholar
  31. Putnam PE, Orenstein SR, Wessel HB, et al. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr. 1992;121(6):983–5. ArticleCASPubMedGoogle Scholar
  32. Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20(1):86–9. ArticlePubMedGoogle Scholar
  33. Chicella MF, Batres LA, Heesters MS, et al. Prokinetic drug therapy in children: a review of current options. Ann Pharmacother. 2005;39(4):706–11. ArticleCASPubMedGoogle Scholar
  34. Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev. 2004;4:CD003502. Google Scholar
  35. Ericson JE, Arnold C, Cheeseman J, et al. Use and safety of erythromycin and metoclopramide in hospitalized infants. J Pediatr Gastroenterol Nutr. 2015;61(3):334–9. ArticleCASPubMedPubMed CentralGoogle Scholar
  36. Henzi I, Walder B, Tramer MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth. 1999;83(5):761–71. ArticleCASPubMedGoogle Scholar
  37. Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol. 2015;13(7):1256–63.e1. ArticleCASPubMedGoogle Scholar
  38. Pasternak B, Svanstrom H, Molgaard-Nielsen D, et al. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA. 2013;310(15):1601–11. ArticleCASPubMedGoogle Scholar
  39. Ponte CD, Nappi JM. Review of a new gastrointestinal drug—metoclopramide. Am J Hosp Pharm. 1981;38(6):829–33. CASPubMedGoogle Scholar
  40. Brown JC, Cook MA, Dryburgh JR. Motilin, a gastric motor activity-stimulating polypeptide: final purification, amino acid composition, and C-terminal residues. Gastroenterology. 1972;62(3):401–4. CASPubMedGoogle Scholar
  41. Peeters TL, Bormans V, Vantrappen G. Comparison of motilin binding to crude homogenates of human and canine gastrointestinal smooth muscle tissue. Regul Pept. 1988;23(2):171–82. ArticleCASPubMedGoogle Scholar
  42. Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322(15):1028–31. ArticleCASPubMedGoogle Scholar
  43. Tack J, Janssens J, Vantrappen G, et al. Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology. 1992;103(1):72–9. ArticleCASPubMedGoogle Scholar
  44. Coulie B, Tack J, Peeters T, et al. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut. 1998;43(3):395–400. ArticleCASPubMedPubMed CentralGoogle Scholar
  45. Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology. 1992;102(3):823–8. ArticleCASPubMedGoogle Scholar
  46. Venkatasubramani N, Rudolph CD, Sood MR. Erythromycin lacks colon prokinetic effect in children with functional gastrointestinal disorders: a retrospective study. BMC Gastroenterol. 2008;8:38. ArticlePubMedPubMed CentralCASGoogle Scholar
  47. Dranove J, Horn D, Reddy SN, et al. Effect of intravenous erythromycin on the colonic motility of children and young adults during colonic manometry. J Pediatr Surg. 2010;45(4):777–83. ArticlePubMedGoogle Scholar
  48. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351(11):1089–96. ArticleCASPubMedGoogle Scholar
  49. Milberg P, Eckardt L, Bruns HJ, et al. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes. J Pharmacol Exp Ther. 2002;303(1):218–25. ArticleCASPubMedGoogle Scholar
  50. Wisialowski T, Crimin K, Engtrakul J, et al. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability. J Pharmacol Exp Ther. 2006;318(1):352–9. ArticleCASPubMedGoogle Scholar
  51. Maheshwai N. Are young infants treated with erythromycin at risk for developing hypertrophic pyloric stenosis? Arch Dis Child. 2007;92(3):271–3. ArticlePubMedGoogle Scholar
  52. Ng PC. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants. Neonatology. 2009;95(2):97–104. ArticleCASPubMedGoogle Scholar
  53. Ng YY, Su PH, Chen JY, et al. Efficacy of intermediate-dose oral erythromycin on very low birth weight infants with feeding intolerance. Pediatr Neonatol. 2012;53(1):34–40. ArticlePubMedGoogle Scholar
  54. Briggs GG. Drugs in pregnancy and lactation a reference guide to fetal and neonatal risk on CD-ROM. Philadelphia, PA: Lippincott, Williams & Wilkins; 1999. Google Scholar
  55. Broad J, Sanger GJ. The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol. 2013;168(8):1859–67. ArticleCASPubMedPubMed CentralGoogle Scholar
  56. Moshiree B, McDonald R, Hou W, et al. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010;55(3):675–83. ArticleCASPubMedGoogle Scholar
  57. Chini P, Toskes PP, Waseem S, et al. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol. 2012;47(4):422–7. ArticleCASPubMedGoogle Scholar
  58. Euler AR. Use of bethanechol for the treatment of gastroesophageal reflux. J Pediatr. 1980;96(2):321–4. ArticleCASPubMedGoogle Scholar
  59. Strickland AD, Chang JH. Results of treatment of gastroesophageal reflux with bethanechol. J Pediatr. 1983;103(2):311–5. ArticleCASPubMedGoogle Scholar
  60. Farrell RL, Roling GT, Castell DO. Cholinergic therapy of chronic heartburn. A controlled trial. Ann Intern Med. 1974;80(5):573–6. ArticleCASPubMedGoogle Scholar
  61. Blonski W, Vela MF, Freeman J, et al. The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers. J Clin Gastroenterol. 2009;43(3):253–60. ArticleCASPubMedGoogle Scholar
  62. Sondheimer JM, Arnold GL. Early effects of bethanechol on the esophageal motor function of infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1986;5(1):47–51. ArticleCASPubMedGoogle Scholar
  63. Orenstein SR, Lofton SW, Orenstein DM. Bethanechol for pediatric gastroesophageal reflux: a prospective, blind, controlled study. J Pediatr Gastroenterol Nutr. 1986;5(4):549–55. ArticleCASPubMedGoogle Scholar
  64. Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta. 1985;40(5):349–59. CASPubMedGoogle Scholar
  65. Shermeta DW, Whitington PF, Seto DS, et al. Lower esophageal sphincter dysfunction in esophageal atresia: nocturnal regurgitation and aspiration pneumonia. J Pediatr Surg. 1977;12(6):871–6. ArticleCASPubMedGoogle Scholar
  66. Agrawal A, Hila A, Tutuian R, et al. Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J Clin Gastroenterol. 2007;41(4):366–70. ArticleCASPubMedGoogle Scholar
  67. Lee JW, Bang KW, Jang PS, et al. Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies. Korean J Hematol. 2010;45(1):62–5. ArticleCASPubMedPubMed CentralGoogle Scholar
  68. Kim TS, Lee JW, Kim MJ, et al. Acute colonic pseudo-obstruction in postchemotherapy complication of brain tumor treated with neostigmine. J Pediatr Hematol Oncol. 2007;29(6):420–2. ArticleCASPubMedGoogle Scholar
  69. Gmora S, Poenaru D, Tsai E. Neostigmine for the treatment of pediatric acute colonic pseudo-obstruction. J Pediatr Surg. 2002;37(10):E28. ArticlePubMedGoogle Scholar
  70. Khosla A, Ponsky TA. Acute colonic pseudoobstruction in a child with sickle cell disease treated with neostigmine. J Pediatr Surg. 2008;43(12):2281–4. ArticlePubMedGoogle Scholar
  71. Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015;27(12):1736–46. ArticleCASPubMedGoogle Scholar
  72. Corazziari E, Bontempo I, Anzini F. Effects of cisapride on distal esophageal motility in humans. Dig Dis Sci. 1989;34(10):1600–5. ArticleCASPubMedGoogle Scholar
  73. Veysey MJ, Malcolm P, Mallet AI, et al. Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial. Gut. 2001;49(6):828–34. ArticleCASPubMedPubMed CentralGoogle Scholar
  74. Shulman RJ, Boyle JT, Colletti RB, et al. The use of cisapride in children. The North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 1999;28(5):529–33. ArticleCASPubMedGoogle Scholar
  75. Vandenplas Y. Current pediatric indications for cisapride. J Pediatr Gastroenterol Nutr. 2000;31(5):480–9. ArticleCASPubMedGoogle Scholar
  76. Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev. 2010;4:CD002300. Google Scholar
  77. Levy J, Hayes C, Kern J, et al. Does cisapride influence cardiac rhythm? Results of a United States multicenter, double-blind, placebo-controlled pediatric study. J Pediatr Gastroenterol Nutr. 2001;32(4):458–63. ArticleCASPubMedGoogle Scholar
  78. Cohen RC, O’Loughlin EV, Davidson GP, et al. Cisapride in the control of symptoms in infants with gastroesophageal reflux: a randomized, double-blind, placebo-controlled trial. J Pediatr. 1999;134(3):287–92. ArticleCASPubMedGoogle Scholar
  79. Cucchiara S, Staiano A, Capozzi C, et al. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1987;62(5):454–7. ArticleCASPubMedPubMed CentralGoogle Scholar
  80. Escobar Castro HBFG, Suarez Cortina L, Camarero Salces C, Lima M. Efficacy of cisapride in the treatment of gastroesophageal reflux (GER) in children. Evaluation of a double blind study [Efectividad del Cisapride en el tratamiento del reflujo gastroesofagico (R.G.E.) en ninos. Valoracion de un estudio a doble ciego]. An Esp Pediatr. 1994;40(1):5–8. Google Scholar
  81. Moya MJM, Cortes E, Auxina A, Ortiz L. Clinical evaluation of the different therapeutic possibilities in the treatment of infant regurgitation. [Valoracion clinica de las distintas posibilidades terapeuticas en el manejo de las regurgitaciones del lactante]. Rev Esp Pediatr. 1999;55(3):219–23. Google Scholar
  82. Scott RB, Ferreira C, Smith L, et al. Cisapride in pediatric gastroesophageal reflux. J Pediatr Gastroenterol Nutr. 1997;25(5):499–506. ArticleCASPubMedGoogle Scholar
  83. Van Eygen M, Van Ravensteyn H. Effect of cisapride on excessive regurgitation in infants. Clin Ther. 1989;11(5):669–77. PubMedGoogle Scholar
  84. Vandenplas Y, de Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. J Pediatr Gastroenterol Nutr. 1991;12(1):44–7. ArticleCASPubMedGoogle Scholar
  85. Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2006;43(3):e1–13. ArticleGoogle Scholar
  86. Khongphatthanayothin A, Lane J, Thomas D, et al. Effects of cisapride on QT interval in children. J Pediatr. 1998;133(1):51–6. ArticleCASPubMedGoogle Scholar
  87. Benatar A, Feenstra A, Decraene T, et al. Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography. J Pediatr Gastroenterol Nutr. 2001;33(1):41–6. ArticleCASPubMedGoogle Scholar
  88. Bernardini S, Semama DS, Huet F, et al. Effects of cisapride on QTc interval in neonates. Arch Dis Child Fetal Neonatal Ed. 1997;77(3):F241–3. ArticleCASPubMedPubMed CentralGoogle Scholar
  89. Lupoglazoff JM, Bedu A, Faure C, et al. Long QT syndrome under cisapride in neonates and infants. Arch Pediatr. 1997;4(6):509–14. ArticleCASPubMedGoogle Scholar
  90. Zamora SA, Belli DC, Friedli B, et al. 24-hour electrocardiogram before and during cisapride treatment in neonates and infants. Biol Neonate. 2004;85(4):229–36. ArticleCASPubMedGoogle Scholar
  91. Ward RM, Lemons JA, Molteni RA. Cisapride: a survey of the frequency of use and adverse events in premature newborns. Pediatrics. 1999;103(2):469–72. ArticleCASPubMedGoogle Scholar
  92. Nasr I, Rao SS, Attaluri A, et al. Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study. Indian J Gastroenterol. 2009;28(4):136–42. ArticlePubMedGoogle Scholar
  93. Liem O, Mousa HM, Benninga MA, et al. Tegaserod use in children: a single-center experience. J Pediatr Gastroenterol Nutr. 2008;46(1):54–8. ArticlePubMedGoogle Scholar
  94. Zhou HH, Khalilieh S, Lau H, et al. Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol. 1999;39(9):911–9. ArticleCASPubMedGoogle Scholar
  95. Appel S, Kumle A, Hubert M, et al. First pharmacokinetic-pharmacodynamic study in humans with a selective 5-hydroxytryptamine(4) receptor agonist. J Clin Pharmacol. 1997;37(3):229–37. ArticleCASPubMedGoogle Scholar
  96. Briejer MR, Akkermans LM, Schuurkes JA. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev. 1995;47(4):631–51. CASPubMedGoogle Scholar
  97. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil. 2001;13(5):465–72. ArticleCASPubMedGoogle Scholar
  98. Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil. 2014;26(8):1079–86. ArticleCASPubMedGoogle Scholar
  99. Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57(2):197–203. ArticleCASPubMedGoogle Scholar
  100. Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014;147(6):1285–95.e1. ArticleCASPubMedGoogle Scholar
  101. Emmanuel AV, Kamm MA, Roy AJ, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42(4):511–6. ArticleCASPubMedPubMed CentralGoogle Scholar
  102. Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999;44(5):682–6. ArticleCASPubMedPubMed CentralGoogle Scholar
  103. Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999;13(11):1493–7. ArticleCASPubMedGoogle Scholar
  104. Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16(7):1347–56. ArticleCASPubMedGoogle Scholar
  105. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120(2):354–60. ArticleCASPubMedGoogle Scholar
  106. Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–54. ArticleCASPubMedGoogle Scholar
  107. Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29(3):315–28. ArticleCASPubMedGoogle Scholar
  108. Muller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22(9):991–8.e255. ArticleCASPubMedGoogle Scholar
  109. Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357–65. ArticleCASPubMedGoogle Scholar
  110. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16(4):759–67. ArticleCASPubMedGoogle Scholar
  111. Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21(12):1256–e117. ArticleCASPubMedGoogle Scholar
  112. Dhruva Rao PK, Lewis M, Peiris SP, et al. Long term outcome of Prucalopride for chronic constipation: a single centre study. Colorectal Dis. 2015;17(12):1079–84. ArticleCASPubMedGoogle Scholar
  113. Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110(5):741–8. ArticleCASPubMedPubMed CentralGoogle Scholar
  114. Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation—follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32(9):1113–23. ArticleCASPubMedGoogle Scholar
  115. Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor) in man [abstract no. P0891]. Gut. 2008;21(57 Suppl I):A282. Google Scholar
  116. Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil. 2010;22(1):42–9.e7–8. CASPubMedGoogle Scholar
  117. Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation—a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010;32(9):1102–12. ArticleCASPubMedGoogle Scholar
  118. Peeters TL, Janssens J, Vantrappen GR. Somatostatin and the interdigestive migrating motor complex in man. Regul Pept. 1983;5(3):209–17. ArticleCASPubMedGoogle Scholar
  119. Peeters TL, Romanski KW, Janssens J, et al. Effect of the long-acting somatostatin analogue SMS 201-995 on small-intestinal interdigestive motility in the dog. Scand J Gastroenterol. 1988;23(7):769–74. ArticleCASPubMedGoogle Scholar
  120. Novartis. Sandostatin LAR® Depot (octreotide acetate for injectable suspension) prescribing information. East Hanover, NJ: Novartis; 2006. Google Scholar
  121. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461–7. ArticleCASPubMedGoogle Scholar
  122. Dalgic B, Sari S, Dogan I, et al. Chronic intestinal pseudoobstruction: report of four pediatric patients. Turk J Gastroenterol. 2005;16(2):93–7. PubMedGoogle Scholar
  123. Parashette KR, Waseem S, Horn D, et al. Effect of octreotide on the colonic motility in pediatric patients with chronic recalcitrant constipation. J Pediatr Gastroenterol Nutr. 2015;61(6):626–9. ArticleCASGoogle Scholar
  124. Portenoy RK, Thomas J, Moehl Boatwright ML, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35(5):458–68. ArticleCASPubMedGoogle Scholar
  125. Russell J, Bass P, Goldberg LI, et al. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol. 1982;78(3):255–61. ArticleCASPubMedGoogle Scholar
  126. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology. 1985;24(3):181–91. ArticleCASPubMedGoogle Scholar
  127. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46. CASPubMedGoogle Scholar
  128. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–43. ArticleCASPubMedGoogle Scholar
  129. Bagnol D, Mansour A, Akil H, et al. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997;81(2):579–91. ArticleCASPubMedGoogle Scholar
  130. Churchill GA, Airey DC, Allayee H, et al. The collaborative cross, a community resource for the genetic analysis of complex traits. Nat Genet. 2004;36(11):1133–7. ArticleCASPubMedGoogle Scholar
  131. Deschepper CF, Olson JL, Otis M, et al. Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J Appl Physiol. 2004;97(1):369–76. ArticlePubMedGoogle Scholar
  132. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous Methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–62. ArticleCASPubMedGoogle Scholar
  133. Garten L, Degenhardt P, Buhrer C. Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone. J Pediatr Surg. 2011;46(3):e13–5. ArticlePubMedGoogle Scholar
  134. Flerlage JE, Baker JN. Methylnaltrexone for opioid-induced constipation in children and adolescents and young adults with progressive incurable cancer at the end of life. J Palliat Med. 2015;18(7):631–3. ArticlePubMedPubMed CentralGoogle Scholar
  135. Rodrigues A, Wong C, Mattiussi A, et al. Methylnaltrexone for opioid-induced constipation in pediatric oncology patients. Pediatr Blood Cancer. 2013;60(10):1667–70. ArticleCASPubMedGoogle Scholar
  136. Laubisch JE, Baker JN. Methylnaltrexone use in a seventeen-month-old female with progressive cancer and rectal prolapse. J Palliat Med. 2013;16(11):1486–8. ArticlePubMedPubMed CentralGoogle Scholar
  137. Yeomanson D, Chohan O, Mayer A. Paediatric palliative care: intravenous methylnaltrexone relieves constipation. BMJ Support Palliat Care. 2013;3(1):103–5. ArticlePubMedGoogle Scholar
  138. Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother. 2007;41(6):984–93. ArticleCASPubMedGoogle Scholar
  139. Rotshteyn Y, Boyd TA, Yuan CS. Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration. Expert Opin Drug Metab Toxicol. 2011;7(2):227–35. ArticlePubMedGoogle Scholar
  140. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387–96. ArticlePubMedCASGoogle Scholar
  141. Awouters F, Niemegeers CJ, Janssen PA. Pharmacology of antidiarrheal drugs. Annu Rev Pharmacol Toxicol. 1983;23:279–301. ArticleCASPubMedGoogle Scholar
  142. Gomez R, Fernandez S, Aspirot A, et al. Effect of amoxicillin/clavulanate on gastrointestinal motility in children. J Pediatr Gastroenterol Nutr. 2012;54(6):780–4. ArticleCASPubMedGoogle Scholar
  143. Ericsson CD, Johnson PC. Safety and efficacy of loperamide. Am J Med. 1990;88(6A):10S–4. ArticleCASPubMedGoogle Scholar
  144. Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS Med. 2007;4(3):e98. ArticlePubMedPubMed CentralCASGoogle Scholar
  145. Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci. 1984;29(3):239–47. ArticleCASPubMedGoogle Scholar
  146. Bhutta TI, Tahir KI. Loperamide poisoning in children. Lancet. 1990;335(8685):363. ArticleCASPubMedGoogle Scholar
  147. Thomas TJ, Pauze D, Love JN. Are one or two dangerous? Diphenoxylate-atropine exposure in toddlers. J Emerg Med. 2008;34(1):71–5. ArticlePubMedGoogle Scholar
  148. Firoozabadi A, Mowla A, Farashbandi H, et al. Diphenoxylate hydrochloride dependency. J Psychiatr Pract. 2007;13(4):278–80. ArticlePubMedGoogle Scholar
  149. McCarron MM, Challoner KR, Thompson GA. Diphenoxylate-atropine (Lomotil) overdose in children: an update (report of eight cases and review of the literature). Pediatrics. 1991;87(5):694–700. CASPubMedGoogle Scholar
  150. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2005;2:CD003460. Google Scholar
  151. Myers JH, Moro-Sutherland D, Shook JE. Anticholinergic poisoning in colicky infants treated with hyoscyamine sulfate. Am J Emerg Med. 1997;15(5):532–5. ArticleCASPubMedGoogle Scholar
  152. Hammerle CW, Surawicz CM. Updates on treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2639–49. ArticleCASPubMedPubMed CentralGoogle Scholar
  153. Lehtonen LA, Rautava PT. Infantile colic: natural history and treatment. Curr Probl Pediatr. 1996;26(3):79–85. CASPubMedGoogle Scholar
  154. Hwang CP, Danielsson B. Dicyclomine hydrochloride in infantile colic. Br Med J (Clin Res Ed). 1985;291(6501):1014. ArticleCASGoogle Scholar
  155. Lucassen PL, Assendelft WJ, Gubbels JW, et al. Effectiveness of treatments for infantile colic: systematic review. BMJ. 1998;316(7144):1563–9. ArticleCASPubMedPubMed CentralGoogle Scholar
  156. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol. 1981;3(2):153–6. ArticleCASPubMedGoogle Scholar
  157. Hasler WL. Pharmacotherapy for intestinal motor and sensory disorders. Gastroenterol Clin North Am. 2003;32(2):707–32, viii–ix. ArticlePubMedGoogle Scholar
  158. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2001;15(3):355–61. ArticleCASPubMedGoogle Scholar
  159. Savino F, Brondello C, Cresi F, et al. Cimetropium bromide in the treatment of crisis in infantile colic. J Pediatr Gastroenterol Nutr. 2002;34(4):417–9. ArticleCASPubMedGoogle Scholar
  160. Dobrilla G, Imbimbo BP, Piazzi L, et al. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. Gut. 1990;31(3):355–8. ArticleCASPubMedPubMed CentralGoogle Scholar
  161. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res. 1997;25(5):225–46. CASPubMedGoogle Scholar
  162. Wittmann T, Paradowski L, Ducrotte P, et al. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome—a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2010;31(6):615–24. ArticleCASPubMedGoogle Scholar
  163. Lindqvist S, Hernon J, Sharp P, et al. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol. 2002;137(7):1134–42. ArticleCASPubMedPubMed CentralGoogle Scholar
  164. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des. 2004;10(28):3561–8. ArticleCASPubMedGoogle Scholar
  165. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133(2):136–47. ArticleCASPubMedGoogle Scholar
  166. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547–53. ArticleCASPubMedPubMed CentralGoogle Scholar
  167. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011;8:Cd003460. Google Scholar
  168. Caleo M, Antonucci F, Restani L, et al. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem. 2009;109(1):15–24. ArticleCASPubMedGoogle Scholar
  169. Gutschow CA, Tox U, Leers J, et al. Botox, dilation, or myotomy? Clinical outcome of interventional and surgical therapies for achalasia. Langenbecks Arch Surg. 2010;395(8):1093–9. ArticlePubMedGoogle Scholar
  170. Pehlivanov N, Pasricha PJ. Achalasia: botox, dilatation or laparoscopic surgery in 2006. Neurogastroenterol Motil. 2006;18(9):799–804. ArticleCASPubMedGoogle Scholar
  171. Horgan S, Hudda K, Eubanks T, et al. Does botulinum toxin injection make esophagomyotomy a more difficult operation? Surg Endosc. 1999;13(6):576–9. ArticleCASPubMedGoogle Scholar
  172. Cowgill SM, Villadolid DV, Al-Saadi S, et al. Difficult myotomy is not determined by preoperative therapy and does not impact outcome. JSLS. 2007;11(3):336–43. PubMedPubMed CentralGoogle Scholar
  173. Smith CD, Stival A, Howell DL, et al. Endoscopic therapy for achalasia before Heller myotomy results in worse outcomes than heller myotomy alone. Ann Surg. 2006;243(5):579–84. Discussion 84–6. ArticlePubMedPubMed CentralGoogle Scholar
  174. Peracchia A, Bonavina L. Achalasia: dilation, injection or surgery? Can J Gastroenterol. 2000;14(5):441–3. ArticleCASPubMedGoogle Scholar
  175. Hussain SZ, Thomas R, Tolia V. A review of achalasia in 33 children. Dig Dis Sci. 2002;47(11):2538–43. ArticleCASPubMedGoogle Scholar
  176. Walton JM, Tougas G. Botulinum toxin use in pediatric esophageal achalasia: a case report. J Pediatr Surg. 1997;32(6):916–7. ArticleCASPubMedGoogle Scholar
  177. Mac Iver R, Liptay M, Johnson Y. A case of mediastinitis following botulinum toxin type A treatment for achalasia. Nat Clin Pract Gastroenterol Hepatol. 2007;4(10):579–82. ArticlePubMedGoogle Scholar
  178. Fitzgerald JF, Troncone R, Sukerek H, et al. Clinical quiz. Sinus tract between esophagus and fundus. J Pediatr Gastroenterol Nutr. 2002;35(1):38, 98. ArticlePubMedGoogle Scholar
  179. Koivusalo AI, Pakarinen MP, Rintala RJ. Botox injection treatment for anal outlet obstruction in patients with internal anal sphincter achalasia and Hirschsprung’s disease. Pediatr Surg Int. 2009;25(10):873–6. ArticleCASPubMedGoogle Scholar
  180. Chumpitazi BP, Fishman SJ, Nurko S. Long-term clinical outcome after botulinum toxin injection in children with nonrelaxing internal anal sphincter. Am J Gastroenterol. 2009;104(4):976–83. ArticleCASPubMedGoogle Scholar
  181. Han-Geurts IJ, Hendrix VC, de Blaauw I, et al. Outcome after anal intrasphincteric Botox injection in children with surgically treated Hirschsprung disease. J Pediatr Gastroenterol Nutr. 2014;59(5):604–7. ArticleCASPubMedGoogle Scholar
  182. Husberg B, Malmborg P, Strigard K. Treatment with botulinum toxin in children with chronic anal fissure. Eur J Pediatr Surg. 2009;19(5):290–2. ArticleCASPubMedGoogle Scholar
  183. Nelson R. Non surgical therapy for anal fissure. Cochrane Database Syst Rev. 2006;4:CD003431. Google Scholar
  184. Arts J, Holvoet L, Caenepeel P, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26(9):1251–8. ArticleCASPubMedGoogle Scholar
  185. Rodriguez L, Rosen R, Manfredi M, et al. Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study. Gastrointest Endosc. 2012;75(2):302–9. ArticlePubMedPubMed CentralGoogle Scholar
  186. McEvoy G. Nitrates and nitrites general statement. In: ASoHSP, editor. AHFS drug information. Bethesda, MD: ASoHSP; 2004. p. 1679–84. Google Scholar
  187. Tander B, Guven A, Demirbag S, et al. A prospective, randomized, double-blind, placebo-controlled trial of glyceryl-trinitrate ointment in the treatment of children with anal fissure. J Pediatr Surg. 1999;34(12):1810–2. ArticleCASPubMedGoogle Scholar
  188. Sonmez K, Demirogullari B, Ekingen G, et al. Randomized, placebo-controlled treatment of anal fissure by lidocaine, EMLA, and GTN in children. J Pediatr Surg. 2002;37(9):1313–6. ArticlePubMedGoogle Scholar
  189. Kenny SE, Irvine T, Driver CP, et al. Double blind randomised controlled trial of topical glyceryl trinitrate in anal fissure. Arch Dis Child. 2001;85(5):404–7. ArticleCASPubMedPubMed CentralGoogle Scholar
  190. Simpson J, Lund JN, Thompson RJ, et al. The use of glyceryl trinitrate (GTN) in the treatment of chronic anal fissure in children. Med Sci Monit. 2003;9(10):I123–6. Google Scholar
  191. Demirbag S, Tander B, Atabek C, et al. Long-term results of topical glyceryl trinitrate ointment in children with anal fissure. Ann Trop Paediatr. 2005;25(2):135–7. ArticleCASPubMedGoogle Scholar
  192. Bharucha AE, Trabuco E. Functional and chronic anorectal and pelvic pain disorders. Gastroenterol Clin North Am. 2008;37(3):685–96, ix. ArticlePubMedPubMed CentralGoogle Scholar
  193. Jeyarajah S, Chow A, Ziprin P, et al. Proctalgia fugax, an evidence-based management pathway. Int J Colorectal Dis. 2010;25(9):1037–46. ArticlePubMedGoogle Scholar
  194. Bassotti G, Calcara C, Annese V, et al. Nifedipine and verapamil inhibit the sigmoid colon myoelectric response to eating in healthy volunteers. Dis Colon Rectum. 1998;41(3):377–80. ArticleCASPubMedGoogle Scholar
  195. Chrysos E, Xynos E, Tzovaras G, et al. Effect of nifedipine on rectoanal motility. Dis Colon Rectum. 1996;39(2):212–6. ArticleCASPubMedGoogle Scholar
  196. Glassman MS, Medow MS, Berezin S, et al. Spectrum of esophageal disorders in children with chest pain. Dig Dis Sci. 1992;37(5):663–6. ArticleCASPubMedGoogle Scholar
  197. Richter JE, Dalton CB, Buice RG, et al. Nifedipine: a potent inhibitor of contractions in the body of the human esophagus. Studies in healthy volunteers and patients with the nutcracker esophagus. Gastroenterology. 1985;89(3):549–54. ArticleCASPubMedGoogle Scholar
  198. Maksimak M, Perlmutter DH, Winter HS. The use of nifedipine for the treatment of achalasia in children. J Pediatr Gastroenterol Nutr. 1986;5(6):883–6. ArticleCASPubMedGoogle Scholar
  199. Lacy BE, Weiser K. Esophageal motility disorders: medical therapy. J Clin Gastroenterol. 2008;42(5):652–8. ArticlePubMedGoogle Scholar
  200. Rosen JM, Lavenbarg T, Cocjin J, et al. Diffuse esophageal spasm in children referred for manometry. J Pediatr Gastroenterol Nutr. 2013;56(4):436–8. ArticlePubMedGoogle Scholar
  201. Milov DE, Cynamon HA, Andres JM. Chest pain and dysphagia in adolescents caused by diffuse esophageal spasm. J Pediatr Gastroenterol Nutr. 1989;9(4):450–3. ArticleCASPubMedGoogle Scholar
  202. Freeman L, Mazur LJ. Verapamil therapy for persistent antral spasms in a child. South Med J. 1996;89(5):529–30. ArticleCASPubMedGoogle Scholar
  203. Awad R, Dibildox M, Ortiz F. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. Acta Gastroenterol Latinoam. 1995;25(3):137–44. CASPubMedGoogle Scholar
  204. Lu CL, Chen CY, Chang FY, et al. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2000;15(8):925–30. ArticleCASPubMedGoogle Scholar
  205. Grigoleit HG, Grigoleit P. Gastrointestinal clinical pharmacology of peppermint oil. Phytomedicine. 2005;12(8):607–11. ArticleCASPubMedGoogle Scholar
  206. Asao T, Mochiki E, Suzuki H, et al. An easy method for the intraluminal administration of peppermint oil before colonoscopy and its effectiveness in reducing colonic spasm. Gastrointest Endosc. 2001;53(2):172–7. ArticleCASPubMedGoogle Scholar
  207. Kline RM, Kline JJ, Di Palma J, et al. Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children. J Pediatr. 2001;138(1):125–8. ArticleCASPubMedGoogle Scholar
  208. Liu JH, Chen GH, Yeh HZ, et al. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997;32(6):765–8. ArticleCASPubMedGoogle Scholar
  209. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93(7):1131–5. ArticleCASPubMedGoogle Scholar
  210. Weydert JA, Ball TM, Davis MF. Systematic review of treatments for recurrent abdominal pain. Pediatrics. 2003;111(1):e1–11. ArticlePubMedGoogle Scholar
  211. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505–12. PubMedGoogle Scholar
  212. Huertas-Ceballos AA, Logan S, Bennett C, et al. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev. 2009;1:CD003019. Google Scholar
  213. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(1):S1–35. ArticlePubMedGoogle Scholar
  214. Schumann C. Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr. 2002;41(1):I17–25. PubMedGoogle Scholar
  215. Bennett A, Eley KG. Intestinal pH and propulsion: an explanation of diarrhoea in lactase deficiency and laxation by lactulose. J Pharm Pharmacol. 1976;28(3):192–5. ArticleCASPubMedGoogle Scholar
  216. Bown RL, Gibson JA, Sladen GE, et al. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974;15(12):999–1004. ArticleCASPubMedPubMed CentralGoogle Scholar
  217. Kutsal E, Aydemir C, Eldes N, et al. Severe hypermagnesemia as a result of excessive cathartic ingestion in a child without renal failure. Pediatr Emerg Care. 2007;23(8):570–2. ArticlePubMedGoogle Scholar
  218. McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics. 2000;105(2):E18. ArticleCASPubMedGoogle Scholar
  219. Kinnunen O, Salokannel J. Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. Ann Clin Res. 1987;19(5):321–3. CASPubMedGoogle Scholar
  220. Loening-Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics. 2006;118(2):528–35. ArticlePubMedGoogle Scholar
  221. Pelham RW, Nix LC, Chavira RE, et al. Clinical trial: single- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in healthy young and elderly subjects. Aliment Pharmacol Ther. 2008;28(2):256–65. ArticleCASPubMedGoogle Scholar
  222. Adamiak T, Altaf M, Jensen MK, et al. One-day bowel preparation with polyethylene glycol 3350: an effective regimen for colonoscopy in children. Gastrointest Endosc. 2010;71(3):573–7. ArticlePubMedGoogle Scholar
  223. Pashankar DS, Uc A, Bishop WP. Polyethylene glycol 3350 without electrolytes: a new safe, effective, and palatable bowel preparation for colonoscopy in children. J Pediatr. 2004;144(3):358–62. ArticleCASPubMedGoogle Scholar
  224. Bekkali NL, van den Berg MM, Dijkgraaf MG, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics. 2009;124(6):e1108–15. ArticlePubMedGoogle Scholar
  225. Youssef NN, Peters JM, Henderson W, et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr. 2002;141(3):410–4. ArticleCASPubMedGoogle Scholar
  226. Michail S, Gendy E, Preud’Homme D, et al. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr. 2004;39(2):197–9. ArticleCASPubMedGoogle Scholar
  227. Dupont C, Leluyer B, Maamri N, et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr. 2005;41(5):625–33. ArticleCASPubMedGoogle Scholar
  228. Loening-Baucke V, Krishna R, Pashankar DS. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. J Pediatr Gastroenterol Nutr. 2004;39(5):536–9. ArticleCASPubMedGoogle Scholar
  229. Pashankar DS, Bishop WP, Loening-Baucke V. Long-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children with and without encopresis. Clin Pediatr (Phila). 2003;42(9):815–9. ArticleGoogle Scholar
  230. Lederle FA, Busch DL, Mattox KM, et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. Am J Med. 1990;89(5):597–601. ArticleCASPubMedGoogle Scholar
  231. Ament ME. Malabsorption of apple juice and pear nectar in infants and children: clinical implications. J Am Coll Nutr. 1996;15(5):26S–9. ArticleCASPubMedGoogle Scholar
  232. Smith MM, Davis M, Chasalow FI, et al. Carbohydrate absorption from fruit juice in young children. Pediatrics. 1995;95(3):340–4. CASPubMedGoogle Scholar
  233. Sias SM, Ferreira AS, Daltro PA, et al. Evolution of exogenous lipoid pneumonia in children: clinical aspects, radiological aspects and the role of bronchoalveolar lavage. J Bras Pneumol. 2009;35(9):839–45. ArticlePubMedGoogle Scholar
  234. Bandla HP, Davis SH, Hopkins NE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics. 1999;103(2):E19. ArticleCASPubMedGoogle Scholar
  235. Ciravegna B, Sacco O, Moroni C, et al. Mineral oil lipoid pneumonia in a child with anoxic encephalopathy: treatment by whole lung lavage. Pediatr Pulmonol. 1997;23(3):233–7. ArticleCASPubMedGoogle Scholar
  236. Gal-Ezer S, Shaoul R. The safety of mineral oil in the treatment of constipation—a lesson from prolonged overdose. Clin Pediatr (Phila). 2006;45(9):856–8. ArticleGoogle Scholar
  237. Clark JH, Russell GJ, Fitzgerald JF, et al. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. Am J Dis Child. 1987;141(11):1210–2. CASPubMedGoogle Scholar
  238. Beubler E, Beubler E, Schirgi-Degen A. Stimulation of enterocyte protein kinase C by laxatives in-vitro. J Pharm Pharmacol. 1993;45(1):59–62. ArticleCASPubMedGoogle Scholar
  239. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging. 1998;13(3):245–53. ArticleCASPubMedGoogle Scholar
  240. Taylor I, Duthie HL, Smallwood R, et al. The effect of stimulation on the myoelectrical activity of the rectosigmoid in man. Gut. 1974;15(8):599–607. ArticleCASPubMedPubMed CentralGoogle Scholar
  241. Flig E, Hermann TW, Zabel M. Is bisacodyl absorbed at all from suppositories in man? Int J Pharm. 2000;196(1):11–20. ArticleCASPubMedGoogle Scholar
  242. Roth W, Beschke K. [Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms]. Arzneimittelforschung. 1988;38(4):570–4. CASPubMedGoogle Scholar
  243. Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100(4):936–71. ArticlePubMedGoogle Scholar
  244. Manabe N, Cremonini F, Camilleri M, et al. Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Aliment Pharmacol Ther. 2009;30(9):930–6. ArticleCASPubMedPubMed CentralGoogle Scholar
  245. Herve S, Savoye G, Behbahani A, et al. Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation. Neurogastroenterol Motil. 2004;16(4):397–402. ArticleCASPubMedGoogle Scholar
  246. De Schryver AM, Samsom M, Smout AI. Effects of a meal and bisacodyl on colonic motility in healthy volunteers and patients with slow-transit constipation. Dig Dis Sci. 2003;48(7):1206–12. ArticlePubMedGoogle Scholar
  247. Joo JS, Ehrenpreis ED, Gonzalez L, et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol. 1998;26(4):283–6. ArticleCASPubMedGoogle Scholar
  248. Rawson MD. Cathartic colon. Lancet. 1966;1(7447):1121–4. ArticleCASPubMedGoogle Scholar
  249. Muller-Lissner S. What has happened to the cathartic colon? Gut. 1996;39(3):486–8. ArticleCASPubMedPubMed CentralGoogle Scholar
  250. McEvoy G. AHFS drug information Anthraquinones. Bethesda, MD: American Society of Health-System Pharmacists; 2007. p. 2923–4. Google Scholar
  251. Morales MA, Hernandez D, Bustamante S, et al. Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity? J Toxicol. 2009;2009:287247. ArticleCASPubMedPubMed CentralGoogle Scholar
  252. Gordon M, Naidoo K, Akobeng AK, et al. Cochrane review: osmotic and stimulant laxatives for the management of childhood constipation (review). Evid Based Child Health. 2013;8(1):57–109. ArticlePubMedGoogle Scholar
  253. Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287(5):C1173–83. ArticleCASPubMedGoogle Scholar
  254. Ambizas EM, Ginzburg R. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007;41(6):957–64. ArticleCASPubMedGoogle Scholar
  255. Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290(5):G942–7. ArticleCASPubMedGoogle Scholar
  256. Hyman PE, Di Lorenzo C, Prestridge LL, et al. Lubiprostone for the treatment of functional constipation in children. J Pediatr Gastroenterol Nutr. 2014;58(3):283–91. ArticleCASPubMedGoogle Scholar
  257. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351–61. ArticleCASPubMedGoogle Scholar
  258. Currie MG, Fok KF, Kato J, et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA. 1992;89(3):947–51. ArticleCASPubMedPubMed CentralGoogle Scholar
  259. Forte Jr LR. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther. 2004;104(2):137–62. ArticleCASPubMedGoogle Scholar
  260. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22(3):312–e84. ArticleCASPubMedGoogle Scholar
  261. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139(6):1877–86.e2. ArticleCASPubMedGoogle Scholar
  262. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133(3):761–8. ArticleCASPubMedGoogle Scholar
  263. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol. 2009;104(1):125–32. ArticleCASPubMedGoogle Scholar
  264. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138(3):886–95.e1. ArticleCASPubMedGoogle Scholar

Author information

Authors and Affiliations

  1. Department of Pediatric Gastroenterology, Hepatology and Nutrition, Banner Children’s Diamond Medical Center, University of Arizona, Tucson, AZ, USA Aileen F. Har M.D., B.Ch.
  2. Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Riley Hospital for Children, Indiana University Health, Indianapolis, IN, USA Joseph M. B. Croffie M.D., M.P.H.
  1. Aileen F. Har M.D., B.Ch.